US FDA
21 CFR 211.204 - Returned Drug Products
Plain-language explanation, inspection context and common violation patterns.
What it says
Returned drug products must be identified and held pending investigation, and may only be reprocessed, salvaged or destroyed following a determination that the product meets appropriate standards, with the reason for return, condition of the product and its labeling, and the disposition all documented.
Paraphrased for plain-language clarity. Always verify against the current published regulation text.
What it means in practice
- A returned product is treated as a potential quality event by default, held and investigated, rather than assumed acceptable for redistribution unless proven otherwise.
- The reason a product was returned is itself an important input to the disposition decision - a return for a business reason such as overstock carries different risk than a return citing a suspected quality defect.
- Returned product cannot simply be visually inspected and returned to saleable inventory without a documented determination that it still meets its approved standards.
What FDA inspectors look for
- Whether returned product is genuinely segregated and held pending disposition, rather than commingled with saleable inventory before a decision is made.
- Whether the reason for return is captured and factored into the risk assessment behind the disposition decision.
- Whether returned product that is redistributed has documented evidence supporting that it still meets its approved specifications, not just a visual check.
Most common violation
Returned product redistributed based on visual inspection alone, without documented testing or assessment confirming it still meets approved specifications, particularly when the reason for return is unclear or unconfirmed.
Want a deeper, interactive breakdown?
GMPify's Regulation Explainer tool gives subscribers an AI-powered analysis of any 21 CFR, EU GMP, USP or ICH reference, with live inspection context.
Try the Regulation Explainer →